Analyse Acrivon Therapeutics, Inc. (ACRV) — Kairos Score 64/100

À propos de Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

3 transactions — 0 achats et 2 ventes déclarés par les dirigeants de Acrivon Therapeutics, Inc..

🏦 Hedge Funds

13 fonds institutionnels déclarent une position sur ACRV dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur ACRV.

• Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
• What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.